# MK-1045

Source: https://onco.cc/drugs/mk-1045/  
OnCo record `mk-1045` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MK-1045 is an experimental investigational agent whose form is not stated in the registry from Merck Sharp & Dohme in phase 3 trials for acute lymphoblastic leukaemia, follicular lymphoma and hodgkin lymphoma, aimed at CD19.

## Summary

MK-1045 (CN-201, CN201) is an investigational agent whose form is not stated in the registry developed by Merck Sharp & Dohme and MSD R&D (China). Its target is CD19 (the sponsor names CD19). The sponsor states: MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07570173 (A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukaemia (MK-1045-005)) and NCT07634471 (A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)), in acute lymphoblastic leukaemia, follicular lymphoma, hodgkin lymphoma and diffuse large B-cell lymphoma. The largest, NCT07634471, plans to enrol 960 participants with primary completion expected 2032-07-23. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: CN-201, CN201
- Modality: bispecific antibody (CD3 x CD19, per the sponsor's description; form not stated in the registry record)
- Mechanism: MK-1045 is described as a novel immunotherapy, given intravenously, being compared with blinatumomab in relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia.

## Sources

- ClinicalTrials.gov: trials of MK-1045: https://clinicaltrials.gov/search?intr=CN-201

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)](https://onco.cc/trials/nct05579132/), [A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)](https://onco.cc/trials/nct07519772/), [A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)](https://onco.cc/trials/nct07634471/), [A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)](https://onco.cc/trials/nct07570173/)

---
JSON: https://onco.cc/api/v1/entities/mk-1045.json